Use of cannabis oil
PreclinicalSmall molecule
Use of cannabis oil is one of 36 small molecule programs targeting Fibromyalgia. It is currently in Preclinical.
1
Indications
1
Total Trials
1
Active Trials
35
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
152 competitors in Fibromyalgia
#DrugCompanyPhaseTrials
1Namenda
AbbViePhase 3
Epidiolex
Jazz PharmaceuticalsPhase 3
Xyrem
Jazz PharmaceuticalsPhase 3
Lexapro
AbbViePhase 3
Neurontin
VViatris Specialty LLC
Phase 3
Prozac
VVitae Pharmaceuticals Inc., an Allergan affiliate
Phase 3
DS-5565
Daiichi SankyoPhase 3
Ultram
WWim Janssens
Phase 3
Genotropin
EMD SeronoPhase 3
Feosol
AAuerbach Hematology Oncology Associates P C
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Fibromyalgia1 trial
Use of Cannabis Oil in Fibromyalgia
Active, not recruiting·AAzienda Ospedaliera SS. Antonio e Biagio e Cesare Arrigo di Alessandria··NCT07194018·65 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Use of cannabis oil. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details